Skip to main content
. 2022 Jan 29;17:1. doi: 10.1186/s12263-022-00704-z

Table 1.

Derivation and hypertensive-diabetic subcohort sample characteristics, stratified by incident combined cardiovascular (CV) endpoints

Derivation Subcohort Hypertensive-Diabetic Subcohort
(i) N = 1460 Nil incident event
(ii) N = 3185
Incident CV endpoints(iii) N = 561
Male [n (%)] 786 (53.8%) 1993 (62.6%) 354 (63.1%) < 0.001* 0.81
Age (years) 56.2 ± 11.4 64.7 ± 11.5 71.8 ± 10.4 < 0.001* < 0.001*
Ever smoking [n (%)] 504 (34.5%) 1167 (36.6%) 239 (42.6%) 0.001* 0.007*
Body mass index (kgm-2) 24.0 ± 3.5 25.9 ± 4.1 25.9 ± 4.4 < 0.001* 0.89
Diabetes mellitus [n (%)] 473 (32.4%) 2485 (78.0%) 469 (83.6%) < 0.001* 0.003*
Systolic blood pressure (mmHg) 120.0 ± 14.8 139.3 ± 19.4 141.4 ± 21.9 < 0.001* 0.031*
Diastolic blood pressure (mmHg) 72.1 ± 8.8 75.5 ± 11.0 70.1 ± 11.3 < 0.001* < 0.001*
LDL-cholesterol (mmol/L) 3.1 ± 0.9 2.6 ± 0.9 2.5 ± 1.0 < 0.001* 0.077
HDL-cholesterol (mmol/L) 1.4 ± 0.5 1.24 ± 0.44 1.17 ± 0.33 < 0.001* < 0.001*
Triglycerides (mmol/L) 1.4 ± 1.0 1.6 ± 1.1 1.6 ± 1.2 < 0.001* 0.66
Fasting glucose (mmol/L) 6.8 ± 9.0 7.5 ± 6.3 8.5 ± 10.5 0.001* 0.037*
Creatinine (μmol/L) 79.8 ± 50.1 98.4 ± 74.6 136.6 ± 113.1 < 0.001* < 0.001*
Lipid-lowering therapy [n (%)] 849 (58.2%) 2254 (70.8%) 452 (80.6%) < 0.001* < 0.001*
25-hydroxyvitamin D (Ln) 3.02 ± 0.33 3.01 ± 0.33 2.98 ± 0.38 0.035* 0.043*
Season of recruitment 0.57 0.61
 Spring [n (%)] 225 (15.4%) 515 (16.2%) 88 (15.7%)
 Summer [n (%)] 478 (32.7%) 940 (29.5%) 178 (31.7%)
 Autumn [n (%)] 222 (15.2%) 537 (16.9%) 99 (17.6%)
 Winter [n (%)] 535 (36.6%) 1193 (37.5%) 196 (34.9%)
Vitamin D GRS 2.7 ± 1.2 2.7 ± 1.2 2.5 ± 1.3 0.001* 0.002*

*P < 0.05

P value 1: Group (iii) versus (i)

P value 2: Group (iii) versus (ii)

Natural log-transformed due to skewed distribution

GRS, genetic risk score (linear 0-6) based on allele scoring summation (CYP2R1: rs2060793; GC: rs4588, rs7041)